- Home
- ADIL vs BMRA Comparison
ADIL vs BMRA Comparison
Compare ADIL & BMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADIL
- BMRA
- Stock Information
- Founded
- ADIL 2010
- BMRA 1971
- Country
- ADIL United States
- BMRA United States
- Employees
- ADIL N/A
- BMRA N/A
- Industry
- ADIL Biotechnology: Pharmaceutical Preparations
- BMRA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ADIL Health Care
- BMRA Health Care
- Exchange
- ADIL Nasdaq
- BMRA Nasdaq
- Market Cap
- ADIL 7.6M
- BMRA 8.2M
- IPO Year
- ADIL 2018
- BMRA N/A
- Fundamental
- Price
- ADIL $0.35
- BMRA $2.92
- Analyst Decision
- ADIL Strong Buy
- BMRA
- Analyst Count
- ADIL 1
- BMRA 0
- Target Price
- ADIL $8.00
- BMRA N/A
- AVG Volume (30 Days)
- ADIL 562.1K
- BMRA 425.8K
- Earning Date
- ADIL 11-12-2025
- BMRA 10-14-2025
- Dividend Yield
- ADIL N/A
- BMRA N/A
- EPS Growth
- ADIL N/A
- BMRA N/A
- EPS
- ADIL N/A
- BMRA N/A
- Revenue
- ADIL N/A
- BMRA $5,311,000.00
- Revenue This Year
- ADIL N/A
- BMRA N/A
- Revenue Next Year
- ADIL N/A
- BMRA N/A
- P/E Ratio
- ADIL N/A
- BMRA N/A
- Revenue Growth
- ADIL N/A
- BMRA N/A
- 52 Week Low
- ADIL $0.22
- BMRA $2.08
- 52 Week High
- ADIL $1.30
- BMRA $10.16
- Technical
- Relative Strength Index (RSI)
- ADIL 36.98
- BMRA 43.27
- Support Level
- ADIL $0.36
- BMRA $2.87
- Resistance Level
- ADIL $0.38
- BMRA $3.08
- Average True Range (ATR)
- ADIL 0.02
- BMRA 0.21
- MACD
- ADIL 0.00
- BMRA 0.01
- Stochastic Oscillator
- ADIL 14.00
- BMRA 54.93
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.